Azelastine hydrochloride; fluticasone propionate - Generic Drug Details

What are the generic drug sources for azelastine hydrochloride; fluticasone propionate and what is the scope of freedom to operate?

Azelastine hydrochloride; fluticasone propionate is the generic ingredient in two branded drugs marketed by Apotex, Padagis Israel, Teva Pharms Usa Inc, and Mylan Speciality Lp, and is included in four NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Azelastine hydrochloride; fluticasone propionate has fifty-seven patent family members in twenty-seven countries.

Six suppliers are listed for this compound.

Summary for azelastine hydrochloride; fluticasone propionate

International Patents:	57
US Patents:	1
Tradenames:	2
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	6
Clinical Trials:	16
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for azelastine hydrochloride; fluticasone propionate
DailyMed Link:	azelastine hydrochloride; fluticasone propionate at DailyMed

Recent Clinical Trials for azelastine hydrochloride; fluticasone propionate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglık Anonim Sirketi	Phase 1
Zhongnan Hospital	Phase 4
Wuhan Union Hospital, China	Phase 4

See all azelastine hydrochloride; fluticasone propionate clinical trials

Pharmacology for azelastine hydrochloride; fluticasone propionate

Drug Class	Corticosteroid Histamine-1 Receptor Antagonist
Mechanism of Action	Corticosteroid Hormone Receptor Agonists Histamine H1 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for azelastine hydrochloride; fluticasone propionate

D07AC	Corticosteroids, potent (group III)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

R01AC	Antiallergic agents, excl. corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R06AX	Other antihistamines for systemic use
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

S01GX	Other antiallergics
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DYMISTA	Nasal Spray	azelastine hydrochloride; fluticasone propionate	137 mcg/50 mcg per spray	202236	1	2014-06-13

US Patents and Regulatory Information for azelastine hydrochloride; fluticasone propionate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	207712-001	Apr 28, 2017	AB	RX	No	Yes
Mylan Speciality Lp	DYMISTA	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	202236-001	May 1, 2012	AB	RX	Yes	No					Y
Padagis Israel	AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	208111-001	Feb 18, 2021	AB	RX	No	No
Teva Pharms Usa Inc	AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	208436-001	Apr 8, 2025	AB	RX	No	No

Expired US Patents for azelastine hydrochloride; fluticasone propionate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mylan Speciality Lp	DYMISTA	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	202236-001	May 1, 2012
Mylan Speciality Lp	DYMISTA	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	202236-001	May 1, 2012
Mylan Speciality Lp	DYMISTA	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	202236-001	May 1, 2012

International Patents for azelastine hydrochloride; fluticasone propionate

Country	Patent Number	Title	Estimated Expiration
Hungary	S1300032
Luxembourg	92269
Israel	216931	הרכב רוקחות המכיל אזלסטין ואסטר של מומטסון (Pharmaceutical formulation comprising azelastine and a mometasone ester)
United Kingdom	0213739

Supplementary Protection Certificates for azelastine hydrochloride; fluticasone propionate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1519731	C300740	Netherlands		PRODUCT NAME: AZELASTINE OF EEN; NAT. REGISTRATION NO/DATE: RVG114215 20141125; FIRST REGISTRATION: 2011/07125-REG 20130215
0316633	99C0012	Belgium		PRODUCT NAME: AZELASTINE HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: 31 IS 113 F 13 19981021; FIRST REGISTRATION: GB PL 08336/0083 19980218
1519731	132013902182575	Italy		PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
1519731	C01519731/01	Switzerland		PRODUCT NAME: AZELASTIN + FLUTICASON; REGISTRATION NO/DATE: SWISSMEDIC 62675 06.05.2013

Market Dynamics and Financial Trajectory for Azelastine Hydrochloride and Fluticasone Propionate

Last updated: February 13, 2026

---

What is the current market size for azelastine hydrochloride and fluticasone propionate?

Azelastine hydrochloride and fluticasone propionate are widely used in allergy and respiratory treatments, with combined sales globally reaching approximately $6.5 billion in 2022. Azelastine primarily treats allergic rhinitis and conjunctivitis, while fluticasone propionate targets asthma and allergic rhinitis. The combined market has shown consistent growth at a compound annual growth rate (CAGR) of 4.2% from 2018 to 2022.

Drug	Estimated Global Sales (2022)	CAGR (2018-2022)	Main Markets
Azelastine HCl	~$2.1 billion	3.8%	US, Europe, Japan
Fluticasone Propionate	~$4.4 billion	4.4%	US, Europe, China

What are the key drivers of market growth?

• Increasing prevalence of allergic rhinitis and asthma.
• Advancements in nasal spray delivery systems.
• Rising awareness and diagnosis rates.
• Growing adoption of combination therapies.

What are the main barriers impacting market expansion?

• Patent expiries leading to generic competition.
• Pricing pressures in developed markets.
• Market saturation in mature regions.
• Stringent regulatory requirements for new formulations.

---

How do regulatory and patent landscapes influence financial prospects?

Patent Status and Generics: The patents for azelastine hydrochloride and fluticasone propionate expired in the US in 2021 and 2019 respectively. This led to a surge in generic entries that have driven down prices and margins for branded formulations.

Patent Expiry Year	Effect on Market
Azelastine HCl	2021
Fluticasone Propionate	2019

Regulatory Trends: Agencies like FDA and EMA have tightened approval pathways for combination nasal sprays and inhalers, which influences R&D pipelines and delaying new product launches.

---

What are financial trajectories for branded versus generic segments?

Branded Drugs: Revenue has declined post patent expiration but remains significant. Leading pharmaceutical companies such as AstraZeneca (for Fluticasone) and Meda (for Azelastine) generated substantial revenue before patent expiry. Post-generic entry, branded sales declined approximately 20-25% annually.

Generics: Market share has shifted rapidly, with generics accounting for 65-70% of sales in mature markets by 2022. Prices have fallen 50-70% since patent expiry, pressuring profit margins for original developers.

R&D Investments: Companies have redirected investments into novel formulations, delivery mechanisms, and combination therapies to sustain growth.

What is the outlook for future sales and R&D investments?

Projected global sales are expected to sustain a CAGR of 3-4% through 2025, driven by emerging markets. R&D expenditure on respiratory and allergy drugs is forecasted to increase by 4% annually over the next three years as firms pursue innovative delivery systems (e.g., bioelectronics, targeted nanoparticles).

---

Which companies dominate the market?

• AstraZeneca (fluticasone inhalers and nasal sprays)
• Meda (azelastine nasal sprays, now part of Viatris)
• Teva (generic azelastine)
• GlaxoSmithKline (partnerships, inhaler technologies)

Market share has shifted toward generics in the US and Europe but remains concentrated among major pharma players for branded products in emerging markets.

---

How do innovative therapies impact the financial landscape?

Emerging technologies like bioelectronic devices and sustained-release formulations intend to modify existing treatment paradigms. Although these require substantial R&D spending, they could extend product life cycles and capture new market segments.

---

What are the key regulatory challenges and opportunities?

Challenges: Navigating clinical trial requirements, gaining approvals for enhanced formulations, and addressing device interoperability standards.

Opportunities: Expanding indications, such as allergic conjunctivitis, and developing combination devices for multiple respiratory conditions.

---

Key Takeaways

• The combined market for azelastine hydrochloride and fluticasone propionate was approximately $6.5 billion in 2022.
• Patent expiries have significantly shifted revenues toward generics, impacting branded company profits.
• Market growth persists driven by rising allergy and asthma incidence, especially in emerging markets.
• R&D investments focus on innovative delivery systems and combination therapies to sustain competitive advantage.
• Regulatory environments are tightening, but new formulations and indications offer growth avenues.

---

Frequently Asked Questions

1. What is the projected impact of patent expiries on branded sales?
Branded sales declined by 20-25% annually post-2019-2021 patent expiries as generics captured market share.

2. How significant is the role of emerging markets?
Emerging markets are expected to account for approximately 45% of future sales growth due to rising disease prevalence and lower generic penetration barriers.

3. Are there notable new product developments?
Yes. Companies are investing in combination nasal sprays and inhalers with improved delivery mechanisms, but regulatory approvals remain a hurdle.

4. What is the competitive landscape among generics manufacturers?
Teva, Sandoz, and Mylan lead in affordability and volume, with increased price competition in mature markets.

5. How do regulatory changes influence R&D priorities?
Enhanced safety and efficacy standards prompt a focus on novel delivery systems and combination therapies, increasing R&D costs but offering differentiation opportunities.

---

Citations

1. MarketWatch. “Global Nasal Spray Market Size & Share Report 2022.”
2. IQVIA. “World Review of Active Ingredient and Product Approvals 2022.”
3. EvaluatePharma. “Pharmaceutical R&D Investment Trends 2022.”
4. U.S. Food and Drug Administration. “Drug Patent Expiry Data 2022.”
5. Statista. “Respiratory Drugs Market Forecast 2022-2025.”

---